Mark Kendall
Geen lopende functies
Profiel
Mark Kendall was the founder of Vaxxas Pty Ltd., where he held the title of Chief Technical Officer from 2011 to 2012.
He also worked as an Associate Director at the University of Oxford and as a Professor at the University of Queensland.
Dr. Kendall received his undergraduate and doctorate degrees from the University of Queensland.
Eerdere bekende functies van Mark Kendall
| Bedrijven | Functie | Einde |
|---|---|---|
| The University of Queensland | Corporate Officer/Principal | - |
| University of Oxford | Corporate Officer/Principal | - |
Vaxxas Pty Ltd.
 Vaxxas Pty Ltd. Medical SpecialtiesHealth Technology Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia. | Oprichter | - |
Opleiding van Mark Kendall
| The University of Queensland | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Vaxxas Pty Ltd.
Vaxxas Pty Ltd. Medical SpecialtiesHealth Technology Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia. | Health Technology |
